Cellbion Submits Phase 3 Clinical Trial Plan Approval Request for Lutetium177 DGUL in Metastatic Castration-Resistant Prostate Cancer, Limited Immediate Shareholder Value Impact
Cellbion submitted a Phase 3 clinical trial plan approval request to the Ministry of Food and Drug Safety on June 30, 2026 for Lutetium177 DGUL in metastatic castration-resistant prostate cancer.
This is a multicenter, open-label, randomized trial with 150 patients, evaluating progression-free survival of Lutetium177 DGUL plus best supportive care versus best supportive care alone.
The probability of final drug approval is statistically around 10%, and clinical results may lead to changes in commercialization plans, posing investment risks.
This disclosure is an administrative submission with no direct capital changes or dividend policy adjustments, so near-term shareholder value impact is limited.
[AI Summary]Cellbion's Phase 3 IND submission for Lutetium177 DGUL is a development milestone but not an approval, with a low 10% statistical success rate, limiting immediate shareholder value. Investors must consider the uncertainty of clinical outcomes.
KOSDAQ Filing Information
Major Management Matters Related To Investment Decision (Clinical Trial Plan Approval Application) - (Application For Approval Of A Phase 3 Clinical Trial To Evaluate The Efficacy And Safety Of Lutetium (177Lu) DGUL (Pocuvoitide Satertracetan) In Patients With Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Open-Label, Randomized Trial)